Archive for February 2019
Profile of the SeptiCyte™ LAB gene expression assay to diagnose infection in critically ill patients.
Sepsis is a severe and frequently occurring clinical syndrome, caused by the inflammatory response to infections. Recent studies on the human transcriptome during sepsis have yielded several gene-expression assays that might assist physicians during clinical assessment of patients suspected of sepsis. SeptiCyte™ LAB (Immunexpress, Seattle, WA) is the first gene expression assay that was cleared…
Read MoreDisagreement in Sepsis Diagnosis is Associated with Significant Antibiotic Overprescription
Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body’s overwhelming immune response to an infection, which can lead to tissue…
Read MoreMedical Device Daily – Other News to Note
Immunexpress Inc., of Seattle, reported a partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which the Division of Research, Innovation…
Read MoreImmunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
Immunexpress said today that it has received a funding commitment of $744,739 from the US Department of Health and Human Services (HHS) for the development and commercialization of its SeptiCyte sample-to-result sepsis assay. The RT-qPCR assay, which received US Food and Drug Administration 510(k) clearance in early 2017, is designed to rapidly differentiate infection-positive…
Read MoreImmunexpress Secures BARDA Contract for the Continued Development of SeptiCyte™ for the Rapid and Accurate Diagnosis of Sepsis
Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress’ SeptiCyte™ technology on the Biocartis Idylla™ platform. This development will result in a tool capable of a 90-minute, sample-to-result diagnosis in patients suspected of sepsis. DRIVe (Division of…
Read More